8-K: Know Labs Regains Compliance: NYSE American to Lift Trading Suspension

Know Labs, Inc. announces that the NYSE American will lift the trading suspension of its common stock, effective March 5, 2025, after resolving a listing deficiency related to low selling price.

Summary

• Know Labs, Inc. received notification from NYSE American on February 27, 2025, that it has resolved the continued listing deficiency related to low selling price.
• NYSE Regulation will withdraw its delisting determination and lift the trading suspension of the company's common stock.
• Trading will resume on NYSE American on Wednesday, March 5, 2025, under the symbol KNW.
• Know Labs must still regain compliance with other continued listing standards by March 27, 2026, as per the plan accepted by the NYSE on December 10, 2024.
• Failure to meet these requirements could lead to future delisting proceedings.
• The company is developing a non-invasive glucose monitor that will require FDA clearance.
• Know Labs' technology uses radio frequency dielectric spectroscopy (RFDS) to identify and monitor analytes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has resolved a key listing deficiency and is resuming trading, but risks remain regarding long-term compliance and product development.

Positives

• Know Labs has resolved the immediate delisting concern related to low selling price.
• The NYSE American will lift the trading suspension, allowing the company's stock to resume trading.
• The company has a plan in place, accepted by the NYSE, to regain full compliance with continued listing standards by March 27, 2026.
• The company's RFDS technology has potential applications in various wearable, mobile, and bench-top form factors.
• The company is developing a non-invasive glucose monitor, which could provide accessible and affordable real-time information on blood glucose levels.

Negatives

• Know Labs still needs to regain compliance with other continued listing standards by March 27, 2026.
• Failure to regain compliance could lead to future delisting proceedings.
• There is no assurance that Know Labs will be able to regain compliance within the plan period.
• The non-invasive glucose monitor requires FDA clearance before it can be introduced to the market.

Risks

• Failure to meet the requirements to regain compliance with NYSE American continued listing standards by March 27, 2026, could result in delisting.
• The company's plan to regain compliance may not be successful.
• The non-invasive glucose monitor requires FDA clearance, which may be delayed or not granted.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

Know Labs intends to regain compliance with NYSE American's continued listing standards by March 27, 2026, and is focused on developing its RFDS technology, including a non-invasive glucose monitor.

Industry Context

The development of non-invasive glucose monitoring technology is a competitive area, with numerous companies seeking to provide more convenient and accessible solutions for diabetes management. Know Labs' RFDS technology represents a novel approach to this challenge.

Stakeholder Impact

• Shareholders will benefit from the resumption of trading of Know Labs' common stock.
• The company's employees will continue to work towards the development and commercialization of its technology.
• Customers may benefit from the development of a non-invasive glucose monitor.
• The company's suppliers and creditors will continue to support its operations.

Next Steps

• Know Labs will continue to implement its plan to regain compliance with NYSE American continued listing standards.
• The company will work towards obtaining FDA clearance for its non-invasive glucose monitor.
• Know Labs will continue to develop and commercialize its RFDS technology.

Key Dates